Skip to main content

Advertisement

SpringerLink
Log in

Potential benefits and related treatment effects of calcineurin inhibitors combined with steroid for IgA nephropathy: a systematic review and meta-analysis

  • Nephrology - Review
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Background

IgA nephropathy is not uncommon for clinical practice. Within multiple options of treatment, it is alternatively to consider less well-studied immunosuppressants such as calcineurin inhibitors (CNI). The knowledge of CNI with steroid in the treatment of IgA nephropathy can be clarified via a systematic review and meta-analysis of randomized clinical trials.

Methods

We performed the systematic search and meta-analysis for the randomized clinical trials of the CNI treatment in IgA nephropathy. The comparison between CNI combined with steroid and steroid-alone treatment was performed to find if the CNI combined with steroid can achieve more complete remission for IgA nephropathy. In addition, the related treatment effects were analyzed. After restricted selection, 16 studies with a total of 998 subjects with IgA nephropathy were enrolled. The focused outcome was complete remission, proteinuria, serum creatinine, and estimated glomerular filtration rate.

Results

The meta-analysis showed higher odds ratio of complete remission if the patients received CNI with steroid combined treatment. The proteinuria can be significantly reduced under the combined treatment of CNI and steroid. However, the CNI with steroid combined treatment showed a non-superior effect on the parameters of serum creatinine and estimated glomerular filtration rate.

Conclusions

In current meta-analysis, the CNI combined with steroid treatment might show a trend to achieve complete remission status and reduce the proteinuria of IgA nephropathy when compared to steroid-alone treatment. However, no significant effects were observed in parameters of serum creatinine and estimated glomerular filtration rate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Rajasekaran A, Julian BA, Rizk DV (2021) IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci 361(2):176–194

    Article  PubMed  Google Scholar 

  2. Moriyama T (2019) Clinical and histological features and therapeutic strategies for IgA nephropathy. Clin Exp Nephrol 23(9):1089–1099

    Article  PubMed  Google Scholar 

  3. Rodrigues JC, Haas M, Reich HN (2017) IgA Nephropathy. Clin J Am Soc Nephrol CJASN 12(4):677–686

    Article  CAS  PubMed  Google Scholar 

  4. Coppo R (2017) Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients. J Nephrol 30(3):339–346

    Article  CAS  PubMed  Google Scholar 

  5. Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney international. 2021 Oct;100(4):S1-S276.

  6. Song YH, Cai GY, Xiao YF, Wang YP, Yuan BS, Xia YY et al (2017) Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis. BMC Nephrol 18(1):61

    Article  PubMed  PubMed Central  Google Scholar 

  7. Zhang Y, Luo J, Hu B, Ma T (2018) Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy: a meta-analysis. J Int Med Res 46(8):3236–3250

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Liu H, Xu X, Fang Y, Ji J, Zhang X, Yuan M et al (2014) Comparison of glucocorticoids alone and combined with cyclosporine a in patients with IgA nephropathy: a prospective randomized controlled trial. Intern Med 53(7):675–681

    Article  CAS  PubMed  Google Scholar 

  9. Kim YC, Chin HJ, Koo HS, Kim S (2013) Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy. PLoS ONE 8(8):e71545

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P et al (2011) Cyclosporine A vs. methylprednisolone for Henoch-Schonlein nephritis: a randomized trial. Pediatr Nephrol 26(12):2159–2166

    Article  PubMed  Google Scholar 

  11. Schiele J, Nowack R, Julian BA, van der Woude FJ (1999) Treatment of immunoglobulin A nephropathy. Ann Med Intern 150(2):127–136

    CAS  Google Scholar 

  12. Lai KN, Lam CW, Cheng IK, Tam JS, Lai FM (1991) Effect of cyclosporine A on circulating immune complexes in IgA nephropathy. Int Urol Nephrol 23(3):265–274

    Article  CAS  PubMed  Google Scholar 

  13. Lai KN, Mac-Moune Lai F, Vallance-Owen J (1988) A short-term controlled trial of cyclosporine A in IgA nephropathy. Transpl Proc 20(3 Suppl 4):297–303

    CAS  Google Scholar 

  14. Hong M, Zhang DW, Mei YM (2016) Tacrolimus combined with low-dose glucocorticoid clinical effect on patients with northern IgA nephropathy. Clin J Med Off 44:253–258

    CAS  Google Scholar 

  15. Li Z, Wang FP (2020) Therapeutic effects of tacrolimus combined with low-dose glucocorticoid on IgA nephropathy and the changes of IL-17 and IL-23 levels. Hebei Med J 11:1681–1683

    Google Scholar 

  16. Liu JJ, Huang YH, Peng YM (2015) Effect of cyclosporine combined with glucocorticoids on IgA, C3 and IgA/C3 in patients with IgA nephropathy. Prog Modern Biomed 15(25):4885–4891

    CAS  Google Scholar 

  17. Knobloch K, Yoon U, Vogt PM (2011) Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Cranio-Maxillo-Facial surg 39(2):91–92

    Article  Google Scholar 

  18. Bao HM, Guo WG, Ren Z (2016) Curative effect observation of tacrolimus combined with glucocorticoid in the treatment of primary iga nephropathy with mild to moderate renal injury. Med Recaputulate 22:2884–2887

    Google Scholar 

  19. Gan XH, Wang S (2016) Efficacy and safety of tacrolimus combined with corticosteroids in the treatment of primary IgA nephropathy with mild to moderate renal impairment. J Community Med 24:31–32

    Google Scholar 

  20. Liao D, Xiao H, Jiang D (2013) Tacrolimus in treatment of refractory IgA nephropathy: a clinical observation. Chin Health Care Nutr 9:16–17

    Google Scholar 

  21. Ouyang HY (2015) Clinical efficacy and safety of cyclosporine A combined with glucocorticoid in the treatment of immunoglobulin A nephropathy with large number of protein urine. Chin J Chin Pharmacol 31(18):1825–1827

    CAS  Google Scholar 

  22. Shen P, Li Y, Wang Z, Wang W, Ren H, Zhang W (2013) A prospective randomized study on the effiicacy of corticosteroid combined with cyclophosphamide or FK506 in primary IGA nephropathy with mild or moderate renal injury. Nephro Dia Transplant 28(Suppl 1):i175

    Google Scholar 

  23. Shen PY, Jia XY, Wang CH (2014) The treatment of tacrolimus in primary IgA nephropathy with mild or moderate renal injury: a randomized controlled study. Chin J Nehphrol 30:885–890

    CAS  Google Scholar 

  24. Song YY (2010) Effects of Tacrolimus (FK506) combined with low-dose glucocorticoid in the treatment of IgA Nephropathy. J Jilin Univ 20:11–13

    Google Scholar 

  25. Sun QC, Zhao HF, Li LN (2017) Clinical efficacy of low-dose tacrolimus joint glucocorticoid on IgA nephropathy with moderate proteinuria: a retrospectively trial. J Third Military Med Univ 39:481–486

    Google Scholar 

  26. Tang J (2016) Efficacy of CsA combined with prednison on treatment of IgA nephropathy in children and the effects on IL-18 and ICAM-1. Med J Nat Def Forces Southwest China 11:1239–1241

    Google Scholar 

  27. Wang XW, Wang AW, Zhang QQ, Gui ZH, Hf W (2017) Research of cyclosporine A combined with union/low-dose prednisone on the treatment of progressive IgA nephropathy. Chin J Pharmacoepidemiol 3:168–170

    Google Scholar 

  28. Wu GY, Chen XB, Jiang XL (2015) Clinical study of tacrolimus combined with small dose of prednisolone in treatment of IgA nephropathy. Chin J Prim Med Pham 22:3619–3622

    CAS  Google Scholar 

  29. Xu L, Liu ZC, Guan GJ (2014) Cyclosporine A combined with medium/low dose prednisone in progressive IgA nephropathy. Kaohsiung J Med Sci 30:390–395

    Article  PubMed  Google Scholar 

  30. Zhang JX, Qian JZ (2013) Clinical efficacy of tacrolimus combined with small does of hormone therapy on IgA nephropathy. J Jiangsu Univ 23(3):263–267

    CAS  Google Scholar 

  31. Kim JK, Kim JH, Lee SC, Kang EW, Chang TI, Moon SJ et al (2012) Clinical features and outcomes of IgA nephropathy with nephrotic syndrome. Clin J Am Soc Nephrol CJASN 7(3):427–436

    Article  CAS  PubMed  Google Scholar 

  32. Takada D, Hoshino J, Fujii T, Usui J, Fujii T, Ohashi K et al (2019) Association between renal outcome and the number of steroid pulse therapies after tonsillectomy in patients with IgA nephropathy. Clin Exp Nephrol 23(3):335–341

    Article  CAS  PubMed  Google Scholar 

  33. Leeaphorn N, Garg N, Khankin EV, Cardarelli F, Pavlakis M (2018) Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS/OPTN database. Transplant Int 31(2):175–186

    Article  CAS  Google Scholar 

  34. Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S (1996) Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron 72(2):237–242

    Article  CAS  PubMed  Google Scholar 

  35. Lie DNW, Chan KW, Tang AHN, Chan ATP, Chan GCW, Lai KN et al (2023) Long-term outcomes of add-on direct renin inhibition in igA nephropathy: a propensity score-matched cohort study. J Nephrol. https://doi.org/10.1007/s40620-022-01530-7

    Article  PubMed  Google Scholar 

  36. Goumenos DS, Kalliakmani P, Tsakas S, Savidaki I, Vlachojannis JG (2006) Cyclosporin-A in the treatment of nephrotic syndrome: the importance of monitoring C0 (trough) and C2 (two hours after its administration) blood levels. Med Chem 2(4):391–393

    Article  CAS  PubMed  Google Scholar 

  37. Bartosik LP, Lajoie G, Sugar L, Cattran DC (2001) Predicting progression in IgA nephropathy. Am J Kidney Dis 38(4):728–735

    Article  CAS  PubMed  Google Scholar 

  38. Cai GY, Chen XM (2009) Immunoglobulin A nephropathy in China: progress and challenges. Am J Nephrol 30(3):268–273

    Article  CAS  PubMed  Google Scholar 

  39. Barbour S, Reich H (2018) An update on predicting renal progression in IgA nephropathy. Curr Opin Nephrol Hypertens 27(3):214–220

    Article  CAS  PubMed  Google Scholar 

  40. Arikan H, Koc M, Cakalagaoglu F, Eren Z, Segal MS, Tuglular S et al (2008) Tacrolimus rescue therapy in resistant or relapsing cases of primary glomerulonephritis. J Nephrol 21(5):713–721

    CAS  PubMed  Google Scholar 

  41. Machiguchi T, Tei M, Ono T, Kambara H (2002) Re-biopsy in a patient with IgA nephropathy showing success of treatment with cyclosporin A and angiotensin-II receptor blocker. Clin Exp Nephrol 6(3):166–169

    Article  CAS  PubMed  Google Scholar 

  42. Zhang Q, Shi SF, Zhu L, Lv JC, Liu LJ, Chen YQ et al (2012) Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy. Am J Nephrol 35(4):312–320

    Article  CAS  PubMed  Google Scholar 

  43. Chabova V, Tesar V, Zabka J, Rychlik I, Merta M, Jirsa M Jr et al (2000) Long term treatment of IgA nephropathy with cyclosporine A. Ren Fail 22(1):55–62

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

No relevant funding.

Author information

Author notes

  1. Zhong Li and ZhiQin Yang are co-first authors, they contributed equally to this work.

Authors and Affiliations

  1. Nephrology Department, West China Fourth Hospital, SichuanUniversity, Chengdu, 610041, SiChuan, China

    Zhong Li

  2. Department of Pharmacy, Traditional Chinese Medicine Hospital of Yulin City, Yulin, 719000, Shaanxi, China

    ZhiQin Yang

  3. Department of Internal Medicine, Wuhan University Hospital, Wuhan, 430072, Hubei, China

    MeiXue Ji

Authors
  1. Zhong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. ZhiQin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. MeiXue Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to MeiXue Ji.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Z., Yang, Z. & Ji, M. Potential benefits and related treatment effects of calcineurin inhibitors combined with steroid for IgA nephropathy: a systematic review and meta-analysis. Int Urol Nephrol 55, 2227–2236 (2023). https://doi.org/10.1007/s11255-023-03524-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-023-03524-1

Keywords

Search

Navigation